Nexalin Technology Bilan de santé

Santé financière contrôle des critères 6/6

Nexalin Technology possède un total de capitaux propres de $5.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $5.3M et de $299.4K.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$4.59m
Fonds propres	US$4.96m
Total du passif	US$299.39k
Total des actifs	US$5.26m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NXL ( $4.9M ) dépassent ses passifs à court terme ( $299.4K ).

Passif à long terme: NXL n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: NXL est sans dette.

Réduire la dette: NXL n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NXL dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NXL dispose d'une marge de trésorerie suffisante pour 1.2 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 40.4 % chaque année.

Nexalin Technology Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Nexalin Technology Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2)

Nexalin Technology Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Nexalin Technology, Inc. Provides Non-Compliance Update

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Nexalin Technology Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2)

New major risk - Revenue and earnings growth

Nexalin Technology Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)

New major risk - Market cap size

Nexalin Technology, Inc., Annual General Meeting, Aug 26, 2024

Nexalin Technology, Inc. has completed a Follow-on Equity Offering in the amount of $5.25 million.

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Nexalin Technology, Inc. Provides Non-Compliance Update

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $5.646485 million.

Nexalin Technology Accelerates Manufacturing of Its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board

Full year 2023 earnings released: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Nexalin Technology, Inc. Unveils Gen-3 HALO™? Clarity 15 Milliamp Neurostimulation Device

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.026 loss in 3Q 2022)

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.09 loss in 2Q 2022)

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.08 loss in 1Q 2022)

Full year 2022 earnings released: US$0.30 loss per share (vs US$1.43 loss in FY 2021)

Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Insufficient new directors

Third quarter 2022 earnings released: US$0.026 loss per share (vs US$0.40 loss in 3Q 2021)

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Insufficient new directors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines